Are Patients and Their Providers Talking About Long-Acting Injectable Antiretroviral Therapy? Penetration into Clinical Encounters at Three U.S. Care Sites-Reference-Cited by-同舟云学术

Are Patients and Their Providers Talking About Long-Acting Injectable Antiretroviral Therapy? Penetration into Clinical Encounters at Three U.S. Care Sites

Published:2022-06-11 Issue:7 Volume:9 Page:
ISSN:2328-8957
Container-title:Open Forum Infectious Diseases
language:en
Short-container-title:

Author:

Christopoulos Katerina A¹,Colasanti Jonathan²,Johnson Mallory O³,Diaz Tsuzuki Manami¹,Erguera Xavier A¹,Flores Rey⁴⁵,Kerman Jared⁴⁵,Dance Kaylin²,Sauceda John A³^ORCID,Neilands Torsten B³,Dilworth Samantha E³,Koester Kimberly A³,Gutierrez Jose⁶,Schneider John A⁴⁵,Montgomery Elizabeth⁷⁸,McNulty Moira C⁴⁵

Affiliation:

1. Division of HIV, ID and Global Medicine, Department of Medicine, University of California San Francisco , San Francisco, California , USA

2. Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine , Atlanta, Georgia , USA

3. Center for AIDS Prevention Studies, Division of Prevention Science, Department of Medicine, University of California San Francisco , San Francisco, California , USA

4. Chicago Center for HIV Elimination, University of Chicago , Chicago, Illinois , USA

5. Section of Infectious Diseases and Global Health, Department of Medicine, University of Chicago , Chicago, Illinois , USA

6. National Clinician Scholars Program, University of California San Francisco , San Francisco, California , USA

7. Women's Global Health Imperative, RTI International , Berkeley, California , USA

8. Department of Epidemiology and Biostatistics, School of Medicine, University of California San Francisco , San Francisco, California , USA

Abstract

Abstract Use of long-acting injectable antiretroviral therapy depends on patient awareness, provider discussion, and patient willingness to use. We conducted a postvisit survey with patients at 3 HIV clinics in San Francisco, Chicago, and Atlanta in May 2021 to assess for inequities in these early implementation phases.

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Oncology

Link

https://academic.oup.com/ofid/article-pdf/9/7/ofac293/45034032/ofac293.pdf

Reference17 articles.

1. Routine HIV screening in the emergency department using the new US Centers for Disease Control and Prevention guidelines: results from a high-prevalence area;Brown;J Acquir Immune Defic Syndr,2007

2. The promise of improved adherence with long-acting antiretroviral therapy: what are the data?;Scarsi;J Int Assoc Provid AIDS Care,2021

3. The LAIs are coming! Implementation science considerations for long-acting injectable antiretroviral therapy in the United States: a scoping review;Kanazawa;AIDS Res Hum Retroviruses,2021

4. Multisite study of women living with HIV’s perceived barriers to, and interest in, long-acting injectable antiretroviral therapy;Philbin;J Acquir Immune Defic Syndr,2020

5. Experiences with long acting injectable ART: a qualitative study among PWHIV participating in a phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain;Kerrigan;PLoS One,2018

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Early Implementation and Outcomes Among People with HIV Who Accessed Long-Acting Injectable Cabotegravir/Rilpivirine at Two Ryan White Clinics in the U.S. South;AIDS Research and Human Retroviruses;2024-07-16

2. Engagement in Care, Awareness, and Interest in Long-Acting Injectable Anti-Retroviral Therapy;AIDS and Behavior;2024-07-01

3. Low Uptake of Long-Acting Injectables in the First 2.5 Years Following Approval Among a Cohort of People Living With HIV;Open Forum Infectious Diseases;2024-04-26

4. Likelihood of trying long-acting injectable antiretroviral therapy (LAI ART) among women with HIV in nine sites across the United States;JAIDS Journal of Acquired Immune Deficiency Syndromes;2024-04-12

5. Acceptability of Long-Acting Injectable Antiretroviral Therapy Among People with HIV Receiving Care at Three Ryan White Funded Clinics in the United States;AIDS and Behavior;2024-04-10